This study is looking to test a new imaging method for patients with triple-negative breast cancer (TNBC). TNBC is a type of breast cancer that doesn't have three common receptors found in other breast cancers. The study will use a special imaging technique called positron emission tomography/computed tomography (PET/CT). This technique uses a new drug called 68Ga-DOTA-BPP to help see the cancer better. The goal is to help doctors figure out how well treatments might work for people with TNBC before they start therapy.
- Participants must be between 18-75 years old and have TNBC.
- Exclusions include being pregnant, nursing, or having severe liver or kidney issues.
- This study involves a one-time PET/CT imaging session.
This research might help improve how doctors treat TNBC in the future, letting them tailor treatments to work better for each patient. If you're eligible and interested, participating could aid in advancing breast cancer treatment, but consider the study's requirements and exclusions before deciding.